EZH2 and breast cancer: The expression of EZH2 and SUZ12 was increased in several types of cancers such as prostate, ovarian, and breast cancers, and it initiated tumorigenesis and activated anti-drug responses through preventing the expression of differentiation-related genes and promoting stem cell-like phenotypes (47–50).